JP2015511598A - Ｐａｋ１阻害剤を用いて黒色腫を治療する方法 - Google Patents

Ｐａｋ１阻害剤を用いて黒色腫を治療する方法 Download PDF

Info

Publication number
JP2015511598A
JP2015511598A JP2014561427A JP2014561427A JP2015511598A JP 2015511598 A JP2015511598 A JP 2015511598A JP 2014561427 A JP2014561427 A JP 2014561427A JP 2014561427 A JP2014561427 A JP 2014561427A JP 2015511598 A JP2015511598 A JP 2015511598A
Authority
JP
Japan
Prior art keywords
melanoma
pak1
inhibitor
braf
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014561427A
Other languages
English (en)
Japanese (ja)
Inventor
クラウス ピー． ホーフリッチ，
クラウス ピー． ホーフリッチ，
エイドリアン エム． ジュッブ，
エイドリアン エム． ジュッブ，
ハルトムート ケッペン，
ハルトムート ケッペン，
クリスティー シー． オング，
クリスティー シー． オング，
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2015511598A publication Critical patent/JP2015511598A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014561427A 2012-03-16 2013-03-13 Ｐａｋ１阻害剤を用いて黒色腫を治療する方法 Pending JP2015511598A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612202P 2012-03-16 2012-03-16
US61/612,202 2012-03-16
PCT/EP2013/055085 WO2013135745A1 (en) 2012-03-16 2013-03-13 Methods of treating melanoma with pak1 inhibitors

Publications (1)

Publication Number Publication Date
JP2015511598A true JP2015511598A (ja) 2015-04-20

Family

ID=47846052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014561427A Pending JP2015511598A (ja) 2012-03-16 2013-03-13 Ｐａｋ１阻害剤を用いて黒色腫を治療する方法

Country Status (10)

Country Link
EP (1) EP2844248A1 (zh)
JP (1) JP2015511598A (zh)
KR (1) KR20140135198A (zh)
CN (1) CN104168898A (zh)
BR (1) BR112014020173A8 (zh)
CA (1) CA2860994A1 (zh)
HK (1) HK1200093A1 (zh)
MX (1) MX2014010953A (zh)
RU (1) RU2014141018A (zh)
WO (1) WO2013135745A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139331A1 (en) * 2015-03-05 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of melanoma
KR101730595B1 (ko) 2015-03-18 2017-05-11 충북대학교 산학협력단 Pak4 억제제를 유효성분으로 포함하는 미백 및 멜라닌 색소 과다 침착 질환의 치료용 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
EP1186660A3 (fr) 1985-03-30 2002-03-20 KAUFFMAN, Stuart A. Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009300A1 (en) 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1995034683A1 (en) 1994-06-10 1995-12-21 Symbiotech, Inc. Method of detecting compounds utilizing genetically modified lambdoid bacteriophage
US5627024A (en) 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
AU6785496A (en) 1995-09-07 1997-03-27 Novo Nordisk A/S Phage display for detergent enzyme activity
IL126045A0 (en) 1996-03-20 1999-05-09 Dyax Corp Purification of tissue plasminogen activator (tpa)
CA2256449A1 (en) 1996-06-06 1997-12-11 Lajolla Pharmaceutical Company Apl immunoreactive peptides, conjugates thereof and methods of treatment for apl antibody-mediated pathologies
ATE279203T1 (de) 1996-06-10 2004-10-15 Scripps Research Inst Verwendung von substrat-subtraktionsbibliotheken zur unterscheidung von enzymspezifitäten
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
WO1998014277A1 (en) 1996-10-04 1998-04-09 Whatman, Inc. Device and method for simultaneous multiple chemical syntheses
DE69718341T2 (de) 1996-10-08 2003-10-30 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
EP0938497B1 (en) 1996-11-06 2007-02-28 Genentech, Inc. Constrained helical peptides and methods of making same
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
EP1141708A1 (en) 1998-12-28 2001-10-10 Sunesis Pharmaceuticals Inc. Identifying small organic molecule ligands for binding
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
ES2304531T3 (es) 2002-07-17 2008-10-16 Pfizer Italia S.R.L. Derivados heterobiciclicos de pirazol como inhibidores de quinasa.
PT1838718E (pt) 2005-01-10 2011-08-17 Pfizer Pirrolopirazoles, inibidores potentes da quinase
JP2008534664A (ja) 2005-04-06 2008-08-28 アストラゼネカ アクチボラグ 置換複素環およびｃｈｋ１、ｐｄｋ１及びｐａｋ阻害剤としてのそれらの使用
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
ES2435405T3 (es) 2005-12-21 2013-12-19 Pfizer Products Inc. Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
US20100317715A1 (en) 2007-12-21 2010-12-16 Vollrath Benedikt Methods for treating neuropsychiatric conditions
ES2306630B1 (es) 2008-07-17 2009-06-03 Encarnacion Mira Rodriguez Dispositivo antiflacidez y antiarrugas.
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
US20120283296A1 (en) 2009-10-06 2012-11-08 Afraxis, Inc. Pyrrolopyrazoles for treating cns disorders
WO2011044535A2 (en) 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156640A2 (en) 2010-06-09 2011-12-15 Afraxis, Inc. 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
US8912203B2 (en) 2010-06-09 2014-12-16 Afraxis Holdings, Inc. 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
US20130338153A1 (en) 2010-06-10 2013-12-19 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
US20130252967A1 (en) 2010-06-10 2013-09-26 Afraxis, Inc. 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156786A2 (en) 2010-06-10 2011-12-15 Afraxis, Inc. 6-(ethynyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

Also Published As

Publication number Publication date
HK1200093A1 (zh) 2015-07-31
CA2860994A1 (en) 2013-09-19
BR112014020173A2 (zh) 2017-06-20
RU2014141018A (ru) 2016-05-10
EP2844248A1 (en) 2015-03-11
CN104168898A (zh) 2014-11-26
BR112014020173A8 (pt) 2017-07-11
MX2014010953A (es) 2014-10-13
WO2013135745A1 (en) 2013-09-19
KR20140135198A (ko) 2014-11-25

Similar Documents

Publication Publication Date Title
US11081236B2 (en) Diagnostic and therapeutic methods for the treatment of breast cancer
Lee Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
RU2739942C2 (ru) Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
JP2021168674A (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
CN109890982B (zh) 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法
CN109844536B (zh) 预测对pd-1轴抑制剂的响应
JP2016121176A (ja) ＥｒｂＢ療法に耐性である癌を治療するための方法
JP2023182572A (ja) がんの診断及び治療方法
US20240068047A1 (en) Use of sdha as a prognostic marker and therapeutic target in uveal melanoma
US20230383365A1 (en) Cancer treatments and methods of selecting same
WO2018161081A1 (en) Gene signatures to predict drug response in cancer
TWI567391B (zh) 辨識早期肺腺癌病患之次群組之生物標記
Borneman et al. Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer
EP3798633A1 (en) Predictive biomarkers for treatment of a cancer patient with tgf-beta signaling pathway inhibitors
JP2015511598A (ja) Ｐａｋ１阻害剤を用いて黒色腫を治療する方法
US20140275201A1 (en) Identification of cancer stem cell markers and use of inhibitors thereof to treat cancer
US20220220565A1 (en) Methods and compositions for treating melanoma
CN115003334A (zh) 胰腺癌的治疗和预后
US20230076415A1 (en) Methods and compositions for treating melanoma
US20230416830A1 (en) Methods and compositions for predicting and treating uveal melanoma
LEPORE SIGNORILE p38α, the β-catenin chromatin associated kinase, as promising target in colorectal cancer stem cells for personalized therapy
WO2022003554A1 (en) Biomarkers for pd-1 axis binding antagonist therapy
Greensmith Novel Approaches in the Management of Bladder Cancer
Hajdúch Identification and Characterization of Molecular Basis of Cancer Cell Drug Resistance Mechanisms towards Aurora Kinase Inhibitors CYC116 and ZM447439
Triscott Polo-like kinase 1 as a prognostic and therapeutic target in high-grade brain tumors